Denali Therapeutics Inc. (NASDAQ:DNLI) Director Vicki L. Sato Sells 3,080 Shares

Denali Therapeutics Inc. (NASDAQ:DNLI) Director Vicki L. Sato sold 3,080 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total value of $64,402.80. Following the sale, the director now directly owns 107,976 shares in the company, valued at $2,257,778.16. This trade represents a 2.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Denali Therapeutics Price Performance

Denali Therapeutics stock opened at $21.26 on Friday. The business has a 50 day simple moving average of $24.62 and a 200-day simple moving average of $24.88. Denali Therapeutics Inc. has a 12 month low of $14.56 and a 12 month high of $33.33. The stock has a market capitalization of $3.06 billion, a PE ratio of -7.70 and a beta of 1.39.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period in the prior year, the business posted ($0.72) EPS. As a group, equities research analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Analyst Ratings Changes

DNLI has been the topic of several recent analyst reports. JPMorgan Chase & Co. dropped their price target on shares of Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Raymond James reiterated a “market perform” rating on shares of Denali Therapeutics in a research note on Thursday, October 10th. William Blair initiated coverage on shares of Denali Therapeutics in a research note on Friday. They issued an “outperform” rating for the company. HC Wainwright reiterated a “buy” rating and set a $90.00 target price on shares of Denali Therapeutics in a research report on Thursday, November 7th. Finally, Cantor Fitzgerald downgraded Denali Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 7th. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $40.40.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC boosted its position in shares of Denali Therapeutics by 3,234.3% during the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company’s stock worth $228,128,000 after purchasing an additional 7,596,508 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Denali Therapeutics by 63.2% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company’s stock valued at $109,223,000 after acquiring an additional 1,451,770 shares during the period. Point72 Asset Management L.P. purchased a new stake in shares of Denali Therapeutics during the 2nd quarter worth approximately $24,454,000. Wellington Management Group LLP grew its holdings in shares of Denali Therapeutics by 9.2% in the 3rd quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock worth $312,491,000 after acquiring an additional 903,683 shares during the period. Finally, Integral Health Asset Management LLC purchased a new position in Denali Therapeutics in the 2nd quarter valued at approximately $7,546,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.